Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital.

Q3 Medicine

Acta medica academica Pub Date : 2022-08-01 DOI:10.5644/ama2006-124.374

Rakhmad Hidayat, Alyssa Putri Mustika, Fhathia Avisha, Zlatikha Djuliannisaa, Dinisa Diah Winari, Ria Amiliah Putri, Heydi Marizky Lisman, Vandra Davin, Gemia Clarisa Fathi, Alvina Widhani, Muhammad Hafiz Aini, Yudhistira Yudhistira, Siti Azizah, Meilisa Rahmadani, Novita Dwi Istanti, Astuti Giantini

{"title":"Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital.","authors":"Rakhmad Hidayat, Alyssa Putri Mustika, Fhathia Avisha, Zlatikha Djuliannisaa, Dinisa Diah Winari, Ria Amiliah Putri, Heydi Marizky Lisman, Vandra Davin, Gemia Clarisa Fathi, Alvina Widhani, Muhammad Hafiz Aini, Yudhistira Yudhistira, Siti Azizah, Meilisa Rahmadani, Novita Dwi Istanti, Astuti Giantini","doi":"10.5644/ama2006-124.374","DOIUrl":null,"url":null,"abstract":"Objective: The longevity of vaccine effectiveness and antibody titer after the Moderna mRNA COVID-19 vaccination booster in healthcare workers in Indonesia is not known.Materials and methods: We performed a prospective observational study of healthcare workers at the Universitas Indonesia Hospital after Moderna mRNA COVID-19 booster vaccination. An Immunology Analyzer with Chemiluminescence Immunoassay (CLIA) test was used to examine Anti SARS-CoV-2 S-RBD levels. Antibody levels were classified into two systems (3 categories, and 2 categories).Results: There were 31 male subjects (75.6%), 33 subjects (80.5%) aged 25-39 years, 17 subjects (41.5%) with overweight BMI, 35 subjects (85.4%) without comorbidities, and 29 subjects without previous history of COVID-19 infection (70.7%) who had antibody titer >1000 AU/ml. There were 27 subjects (65.9%) who had a booster shot ≥6 months after the second vaccination with antibody titer >1000 AU/ml. In this study, there was no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.Conclusion: There is no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"51 2","pages":"69-78"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/9a/AMA-51-69.PMC9982858.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica academica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5644/ama2006-124.374","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: The longevity of vaccine effectiveness and antibody titer after the Moderna mRNA COVID-19 vaccination booster in healthcare workers in Indonesia is not known.

Materials and methods: We performed a prospective observational study of healthcare workers at the Universitas Indonesia Hospital after Moderna mRNA COVID-19 booster vaccination. An Immunology Analyzer with Chemiluminescence Immunoassay (CLIA) test was used to examine Anti SARS-CoV-2 S-RBD levels. Antibody levels were classified into two systems (3 categories, and 2 categories).

Results: There were 31 male subjects (75.6%), 33 subjects (80.5%) aged 25-39 years, 17 subjects (41.5%) with overweight BMI, 35 subjects (85.4%) without comorbidities, and 29 subjects without previous history of COVID-19 infection (70.7%) who had antibody titer >1000 AU/ml. There were 27 subjects (65.9%) who had a booster shot ≥6 months after the second vaccination with antibody titer >1000 AU/ml. In this study, there was no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.

Conclusion: There is no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.

Abstract Image

查看原文本刊更多论文

印度尼西亚大学医院第三剂COVID-19 mRNA疫苗接种后SARS-CoV-2抗体反应评价

目的:印度尼西亚卫生保健工作者接种Moderna mRNA COVID-19疫苗增强剂后疫苗有效性和抗体滴度的寿命尚不清楚。材料和方法:我们对印度尼西亚大学医院的医护人员进行了一项前瞻性观察研究，这些医护人员接种了Moderna mRNA COVID-19增强疫苗。采用化学发光免疫分析法(CLIA)检测免疫分析仪检测抗SARS-CoV-2 S-RBD水平。抗体水平分为两个系统(3类和2类)。结果:男性31例(75.6%)，25 ~ 39岁33例(80.5%)，BMI超重17例(41.5%)，无合合症35例(85.4%)，抗体滴度>1000 AU/ml无COVID-19感染史29例(70.7%)。27例(65.9%)在第二次接种后≥6个月接种强化疫苗，抗体滴度>1000 AU/ml。本研究中，抗体滴度与性别、年龄、BMI、合并症、COVID-19感染史、第二次接种与加强接种时间等因素无显著相关性。结论:抗体滴度与性别、年龄、BMI、合并症、COVID-19感染史、第二次接种与加强接种时间等因素无显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊